GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (FRA:CZTA) » Definitions » EV-to-FCF

Checkpoint Therapeutics (FRA:CZTA) EV-to-FCF : -7.20 (As of Mar. 31, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Checkpoint Therapeutics's Enterprise Value is €202.36 Mil. Checkpoint Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-28.12 Mil. Therefore, Checkpoint Therapeutics's EV-to-FCF for today is -7.20.

The historical rank and industry rank for Checkpoint Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:CZTA' s EV-to-FCF Range Over the Past 10 Years
Min: -30.85   Med: -3.31   Max: -0.24
Current: -7.11

During the past 9 years, the highest EV-to-FCF of Checkpoint Therapeutics was -0.24. The lowest was -30.85. And the median was -3.31.

FRA:CZTA's EV-to-FCF is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 3.34 vs FRA:CZTA: -7.11

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-31), Checkpoint Therapeutics's stock price is €3.68. Checkpoint Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.687. Therefore, Checkpoint Therapeutics's PE Ratio (TTM) for today is At Loss.


Checkpoint Therapeutics EV-to-FCF Historical Data

The historical data trend for Checkpoint Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics EV-to-FCF Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -3.13 -8.65 -7.92 -0.67 -1.23

Checkpoint Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -1.23 -1.55 -2.51 -3.18

Competitive Comparison of Checkpoint Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Checkpoint Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's EV-to-FCF falls into.


;
;

Checkpoint Therapeutics EV-to-FCF Calculation

Checkpoint Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=202.356/-28.119
=-7.20

Checkpoint Therapeutics's current Enterprise Value is €202.36 Mil.
Checkpoint Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Checkpoint Therapeutics  (FRA:CZTA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Checkpoint Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.68/-1.687
=At Loss

Checkpoint Therapeutics's share price for today is €3.68.
Checkpoint Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.687.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Checkpoint Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics Headlines

No Headlines